Anaemia and renal dysfunction are independently associated with BNP and NT-proBNP levels in patients with heart failure

Department of Cardiology, Thoraxcenter, University Medical Centre Groningen, University of Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands.
European Journal of Heart Failure (Impact Factor: 6.58). 08/2007; 9(8):787-94. DOI: 10.1016/j.ejheart.2007.04.001
Source: PubMed

ABSTRACT Anaemia may affect B-type natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) levels, but this has not been well described in heart failure (HF) patients without the exclusion of patients with renal dysfunction.
To study the influence of both anaemia and renal function on BNP and NT-proBNP levels in a large group of hospitalised HF patients.
We studied 541 patients hospitalised for HF (mean age 71+/-11 years, 62% male, and left ventricular ejection fraction 0.33+/-0.14). Of these patients, 30% (n=159) were anaemic (women: Hb<7.5 mmol/l, men: Hb<8.1 mmol/l). Of the 159 anaemic patients, 73% had renal dysfunction (eGFR<60 ml/min/1.73 m2) and of the non-anaemic patients, 57% had renal dysfunction. BNP and NT-proBNP levels were measured in all patients before discharge. In multivariable analyses both plasma haemoglobin and eGFR were independently related to the levels of BNP and NT-proBNP (standardised beta's of -0.16, -0.14 [BNP] and -0.19, -0.26 [NT-proBNP] respectively, P-values<0.01).
Anaemia and renal dysfunction are related to increased BNP and NT-proBNP levels, independent of the severity of HF. These results indicate that both anaemia and renal dysfunction should be taken into consideration during the interpretation of BNP and NT-proBNP levels in HF patients.


Available from: Tiny Jaarsma, May 08, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Galectin 3 (G3) is a mediator of fibrosis and remodeling in heart failure. Methods: Patients diagnosed with and treated for Acute Heart Failure Syndromes were prospectively enrolled in the Decision Making in Acute Decompensated Heart Failure multicenter trial. Results: Patients with a higher G3 had a history of renal disease, a lower heart rate and acute kidney injury. They also tended to have a history of HF and 30-day adverse events compared with B-type natriuretic peptide. Conclusion: In Acute Heart Failure Syndromes, G3 levels do not provide prognostic value, but when used complementary to B-type natriuretic peptide, G3 is associated with renal dysfunction and may predict 30-day events.
    Biomarkers 11/2012; 17(8). DOI:10.3109/1354750X.2012.719037 · 2.52 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Although anemia and renal dysfunction are related to increased natriuretic peptides levels in heart failure patients, less is known about this relationship in asymptomatic predialysis patients with chronic kidney disease (CKD). The aim of this study was to investigate relationship between hemoglobin (Hb) concentration, N-terminal proBNP (NT-proBNP) levels and echocardiographic findings in these patients. Methods: The study included 61 patients with CKD stage IV-V (34 male, mean age 62.6 ± 13.6 years) and 22 age- and sex -matched healthy persons as control group. All participants underwent clinical, laboratory and echocardiographic examination, including Tissue Doppler Imaging and colour M-mode Doppler. Results: Patients with CKD had lower Hb levels (p<0.001), and higher levels of NT-proBNP (p<0.001) than healthy controls. Patients were divided into two groups according to their mean Hb levels: group A, Hb<10.3 g/dL and group B, Hb≥10.3 g/dL. Patients from group A was significantly older (p<0.001), left ventricular mass index was significantly higher (LVMI, p<0.001), LV diastolic function was worse (septal and lateral E'/A' ratio: p<0.05 and p<0.01, respectively), and the level NT-proBNP was higher (p<0.001) compared to patients from group B. The natural logarithm of NT-proBNP (lnNT-proBNP) showed highly significant correlation with Hb (p<0.001) and significant correlation with estimated glomerular filtration rate (p=0.035) in CKD patients. Multiple regression analysis revealed Hb levels (p<0.01), cholesterol (p<0.001), LV ejection fraction (p<0.001) and septal E/E' ratio (p<0.01) as the independent variables predicting as much as 54% variability of lnNTpro-BNP. Conclusions: The increased NT-proBNP levels in asymptomatic patients with advanced CKD were independently associated with echocardiographic parameters of LV function, but anemia may represent one of the important confounder of the relationship between NT-proBNP and cardiovascular abnormalities.
    Hippokratia 10/2013; 17(4):307-12. · 0.36 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Autoantibody against β1-adrenergic receptors (β1-AAb) exerts agonist-like action inducing receptor uncoupling and myocardial damage. We attempted to determine the significance of β1-AAb in chronic heart failure (CHF) patients who received carvedilol in the substudy of J-CHF study. In this prospective, randomized, multicenter trial, 117 patients were assigned to 2.5mg/5mg/20mg (n=38/36/43) carvedilol groups according to the target dose. β1-AAb was positive in 51 patients (44%, P) and negative in 66 (N). The % increase of left ventricular ejection fraction during 56 weeks (ΔLVEF) was larger in P than N (p=0.050) and in high titer (H) than low titer group (L) (p=0.04). LV volume decreased to a greater extent in H than L during 56 weeks. β1-AAb titer was significantly correlated with ΔLVEF and the % change of LV volume and was an independent predictor of them. No difference was seen in the composite endpoint (all-cause mortality and hospitalization for cardiovascular diseases or HF). However, in patients with dilated cardiomyopathy, it was more common in 2.5mg group than the other groups in N, which was similar among 3 groups in P. Our data suggest the presence of β1-AAb is associated with favorable response to carvedilol in CHF. Copyright © 2014 Elsevier Inc. All rights reserved.
    Journal of Cardiac Failure 12/2014; 21(3). DOI:10.1016/j.cardfail.2014.12.005 · 3.07 Impact Factor